Glancy Binkow & Goldberg LLP announces that a class action lawsuit has been filed in the United States District Court, Northern District of California on behalf of all those who purchased common stock of Epocrates, Inc. (“Epocrates” or the “Company”) (NASDAQ:EPOC) between February 2, 2011 and August 9, 2011, inclusive (the “Class Period”).

The complaint alleges that, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) the Company's pharmaceutical clients were awaiting guidance from the FDA relating to advertising on the Internet and through social media; (2) these clients were increasingly delaying their marketing activities; (3) the FDA's delay in issuing guidance was causing expanding regulatory queues for Epocrates; (4) these queues were negatively impacting the Company's sales and revenue growth; and (5), as a result, the defendants' positive statements about the Company's business, operations and prospects lacked a reasonable basis and/or were materially false and misleading.

On August 9, 2011, the Company lowered its net sales guidance for 2011 from the range of $122-125 million to the range of $115-120 million because its revenue growth was being negatively impacted by expanding regulatory queues, causing delays in the launch of DocAlert® messages and increasing the time between contract signing and revenue recognition. On this news, shares of Epocrates declined $6.80 per share, nearly 40%, to close on August 10, 2011, at $9.89 per share.

No class has yet been certified in this action. Until a class is certified, you are not represented by counsel unless you retain one. If you purchased Epocrates common stock during the Class Period, you have certain rights, and have until May 7, 2013 to move for lead plaintiff status. To be a member of the class you need not take any action at this time, and you may retain counsel of your choice. If you wish to discuss this action or have any questions concerning your rights or interests regarding these matters, please contact Michael Goldberg, Esquire, of Glancy Binkow & Goldberg LLP, by telephone at 310-201-9150, Toll Free at 888-773-9224, by e-mail to shareholders@glancylaw.com, or visit our website at http://www.glancylaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Epocrates, Inc. (MM) (NASDAQ:EPOC)
Historical Stock Chart
From Oct 2024 to Nov 2024 Click Here for more Epocrates, Inc. (MM) Charts.
Epocrates, Inc. (MM) (NASDAQ:EPOC)
Historical Stock Chart
From Nov 2023 to Nov 2024 Click Here for more Epocrates, Inc. (MM) Charts.